Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

Episode 307

0:00-55:23

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Publisher

Business Of Biotech

Published

May 25, 2026

Duration

55 min

Format

Podcast

Category

Issues · Business

Source

RSS feed

Host

Ben Comer

BO

Business Of Biotech

@businessofbiotech

#rarediseasedrug #zevratherapeuticsneil #management #lifesciences

The Nile